Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + bevacizumab neoadjuvant therapy before resection for resectable hepatocellular carcinoma
ChiCTR2400090752Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Major pathological response. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400090752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090752.